Pharma firms accelerate regional GLP-1 capacity to de-risk supply chains amid geopolitical tensions: GlobalData
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
